NASDAQ · ARTV
Artiva Biotherapeutics, Inc.
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
Loading market information…
NASDAQ · ADVM · USD
Stock price, earnings
Quote as of Dec 9, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Adverum Biotechnologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Adverum Biotechnologies, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a single injection into the vitreous humor of the eye. This treatment is being developed for individuals afflicted with persistent retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies maintains licensing and collaborative partnerships with institutions such as the University of California and Cornell University, as well as companies like GenSight, Lexeo, and Virovek. Established in 2006, the organization was initially named Avalanche Biotechnologies, Inc. before rebranding to Adverum Biotechnologies, Inc. in May 2016. Its headquarters are situated in Redwood City, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 9, 2024 |
| -$1.50-17.19% vs estimate |
| $0.00-100.0% vs estimate |
| Q4 2023 | Mar 18, 2024 | -$2.30+17.86% vs estimate | -$3.60M |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
$7.44-$0.03 (-0.4%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
$1.22+$0.04 (+3.39%)
ALX Oncology Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.14% below the high.
$9.14-$0.15 (-1.61%)
Sutro Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.16% below the high.
$0.86-$0.03 (-3.35%)
Pliant Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.75% below the high.
$0.62-$0.02 (-3.84%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
$0.83+$0.01 (+1.03%)
Metagenomi, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 68.35% below the high.
$5.37+$0.23 (+4.56%)
aTyr Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.91% below the high.
